We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Alliance Pharma Plc | LSE:APH | London | Ordinary Share | GB0031030819 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.60 | -1.78% | 33.10 | 32.95 | 33.85 | 33.95 | 32.95 | 33.95 | 1,864,058 | 16:35:13 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 167.42M | 936k | 0.0017 | 195.88 | 179.87M |
TIDMAPH
RNS Number : 2102J
Alliance Pharma PLC
26 June 2017
For immediate release 26 June 2017
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Changes to interests of a significant shareholder
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, has received a notification of a change in the interests of a significant shareholder. In accordance with AIM rule 17, the following details are now notified:
(a) Identity of the significant shareholder: Mr Nigel Wray
(b) Date of disclosure: 26 June 2017
(c) Date of relevant change: 23 June 2017
(d) Price, amount and class: 8,000,000 ordinary shares of 1p each; price not disclosed
(e) Nature of transaction: sale of shares
(f) Nature and extent of significant shareholder's interest: direct and indirect interests
(g) Resultant shareholding: 1.59% (direct) and 1.59% (indirect) = 3.18% total
In compliance with DTR5, a copy of the notification received from this investor is appended.
For further information:
Alliance Pharma plc + 44 (0) 1249 466966 John Dawson, Chief Executive Andrew Franklin, Chief Financial Officer Rob Bellhouse, Company Secretary www.alliancepharma.co.uk + 44 (0) 20 7466 Buchanan 5000 Mark Court / Sophie Cowles + 44 (0) 20 7260 Numis Securities Limited 1000 Nominated Adviser: Michael Meade / Freddie Barnfield Corporate Broking: James Black / Toby Adcock
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) ------------------------------------------------------------------------------------------------ 1. Identity of the issuer or ALLIANCE PHARMA PLC the underlying issuer of existing shares to which voting rights are attached: (ii) ------------------------------------------------------------- --------------------------------- 2 Reason for the notification (please tick the appropriate box or boxes): ------------------------------------------------------------------------------------------------ An acquisition or disposal of voting rights ----------------------------------------------------------------- ----------------------------- An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached ----------------------------------------------------------------- ----------------------------- An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments ----------------------------------------------------------------- ----------------------------- An event changing the breakdown of voting rights ----------------------------------------------------------------- ----------------------------- Other (please specify): ------------------------------------------------------------ --- ----------------------------- 3. Full name of person(s) NIGEL WRAY subject to the notification obligation: (iii) ------------------------------------------------------------- --------------------------------- 4. Full name of shareholder(s) UBS PRIVATE BANKING NOMINEES (if different from 3.):(iv) LTD ROY NOMINEES LIMITED ------------------------------------------------------------- --------------------------------- 5. Date of the transaction 23 June 2017 and date on which the threshold is crossed or reached: (v) ------------------------------------------------------------- --------------------------------- 6. Date on which issuer 26 June 2017 notified: ------------------------------------------------------------- --------------------------------- 7. Threshold(s) that is/are crossed or reached: (vi, vii) 3% ------------------------------------------------------------- --------------------------------- 8. Notified details: ---------------------------------------------------------------------------------------------------------------------- A: Voting rights attached to shares (viii, ix) ---------------------------------------------------------------------------------------------------------------------- Class/type Situation previous Resulting situation after the of to the triggering triggering transaction shares transaction if possible using the ISIN CODE ------------- -------------------------------- --------------------------------------------------------------------- Number Number Number Number of % of voting of of of voting rights (x) Shares Voting shares rights Rights ------------- --------------- --------------- -------------- -------------------------- ------------------------- Direct Direct Indirect Direct Indirect (xi) (xii) ------------- ----------- ----------- -------------- ------------ ------------ ------------ ----------- Ordinary shares GB0031030819 23,092,593 23,092,593 7,551,269 7,551,269 7,541,324 1.59% 1.59% --------------- --------------- -------------- ------------ ------------ ------------ ----------- B: Qualifying Financial Instruments ---------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ---------------------------------------------------------------------------------------------------------------------- Type of Expiration Exercise/ Number of voting % of voting financial date Conversion rights that rights instrument (xiii) Period (xiv) may be acquired if the instrument is exercised/ converted. ----------------- ------------- ------------------------------- ---------------------------- --------------------- C: Financial Instruments with similar economic effect to Qualifying Financial Instruments (xv, xvi) ---------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ---------------------------------------------------------------------------------------------------------------------- Type of Exercise Expiration Exercise/ Number of voting % of voting financial price date Conversion rights instrument rights (xix, instrument (xvii) period refers to xx) (xviii) --------------- ------------- ------------- ---------------- ---------------------------- ----------------------- Nominal Delta --------------- ------------- ------------- ---------------- ---------------------------- ------------ --------- Total (A+B+C) ---------------------------------------------------------------------------------------------------------------------- Number of voting rights Percentage of voting rights ------------------------------------------------- ------------------------------------------------------------------- 15,092,593 3.18% ------------------------------------------------- ------------------------------------------------------------------- 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: (xxi) --------------------------------------------------------------------------------------- Nigel William Wray has a beneficial interest in shares in Alliance Pharma Plc held by the following nominees 7,551,269 held by UBS Private Banking Nominees Ltd
The family of Nigel Wray maintains a beneficial interest in the shares held by Roy Nominees Limited - 7,541,324 Proxy Voting: --------------------------------------------------------------------------------------- 10. Name of the proxy holder: N/A ------------------------------------------------------- ------------------------------ 11. Number of voting rights proxy N/A holder will cease to hold: ------------------------------------------------------- ------------------------------ 12. Date on which proxy holder will N/A cease to hold voting rights: ------------------------------------------------------- ------------------------------ Figures are based on a total 13. Additional information: number of voting rights of 474,307,589 ------------------------------------------------------- ------------------------------ 14. Contact name: Nigel Wray ------------------------------------------------------- ------------------------------ 15. Contact telephone number: 020 7647 7647 ------------------------------------------------------- ------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLPGUQPQUPMGQQ
(END) Dow Jones Newswires
June 26, 2017 12:31 ET (16:31 GMT)
1 Year Alliance Pharma Chart |
1 Month Alliance Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions